Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 30 results for tremor

  1. Subthalamotomy for Parkinson's disease (IPG65)

    Evidence-based recommendations on subthalamotomy for Parkinson's disease. This involves putting very thin needles into the brain through small holes made in the skull.

  2. Lithium Support Service provided by community pharmacists

    adverse effects including thirst, frequency in passing urine, dry mouth and tremor. Two were identified who had not attended for lithium...

  3. Deep brain stimulation for Parkinson's disease (IPG19)

    Evidence-based recommendations on deep brain stimulation for Parkinson's disease. This involves planting electrodes into the brain and generating electrical currents to reduce the problems caused by Parkinson's disease

  4. Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

    Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making

  5. Cerebral palsy in adults (NG119)

    This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.

  6. Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)

    Evidence-based recommendations on foslevodopa–foscarbidopa (Produodopa) for treating advanced Parkinson’s with motor symptoms in adults.

  7. Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues (IPG666)

    Evidence-based recommendations on reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues. These procedures on high-risk tissues are intradural surgery on the brain (including the pituitary gland) and spinal cord, neuroendoscopy, and surgery on the retina or optic nerve.

  8. Depression in adults: treatment and management (NG222)

    This guideline covers identifying, treating and managing depression in people aged 18 and over. It recommends treatments for first episodes of depression and further-line treatments, and provides advice on preventing relapse, and managing chronic depression, psychotic depression and depression with a coexisting diagnosis of personality disorder.

  9. Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)

    Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.

  10. Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

    Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

  11. Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care (DG35)

    Evidence-based recommendations on lead-I electrocardiogram (ECG) devices (imPulse, Kardia Mobile, MyDiagnostick and Zenicor-ECG) for detecting symptomatic

  12. Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

    Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.

  13. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication (HTE10)

    Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication....

  14. Research recommendations

    unilateral MRI-guided focused ultrasound thalamotomy for moderate to severe tremor in Parkinson's disease, which could include...

  15. NICE recommends NHS collects real-world evidence on devices that monitor people with Parkinson's disease

    Five promising technologies that could help improve symptoms and quality of life for people with Parkinson’s disease have been conditionally recommended by NICE.